Jun
10
2020

Surgery Versus ATMPs: An Example From Ophthalmology

Frontiers in Bioengineering & Biotechnology

Beyond the value of ATMPs for healthcare and considering the total cost for a single patient, it is important to consider healthcare-related costs as well as non-healthcare and indirect costs to perform an appropriate evaluation. It is necessary to have a holistic view on expenses for the government, especially in the case of therapies with high up-front costs.

May
25
2020

Could Cell Therapy Target the Symptoms of Severe Covid-19?

Labiotech

The excessive inflammatory response seen in the most serious cases of Covid-19, along with shortages of ventilators, has caused a healthcare crisis in many countries around the world. Could cell therapy provide an answer to this dilemma?

May
24
2020

Gene Therapy Trends and Future Prospects

BioProcess International

Gene therapy is defined as the transfer of genetic information to a patient for treatment of a disease. Clinical investigation of such therapies began in 1990 with a treatment for a rare immunodeficiency disorder and since has expanded to almost 1,000 clinical studies in 2019. In its most straightforward incarnation, the goal of gene therapy for genetic diseases is long-term expression of a transferred gene at levels that are high enough to be therapeutic.

May
20
2020

Medicare's CAR-T Payment Change Helps the Entire Regenerative Medicine Field ... A Little Bit

Pink Sheet

The Alliance for Regenerative Medicine (ARM) says CMS’ plan to create new reimbursement category for CAR-T helps validate entire field, but it may not make it any easier for other products to navigate the payment landscape. ARM is prioritizing value-based payment legislation in its Congressional lobbying.

May
11
2020